NanoRepro AG Sets Ambitious Revenue Targets Amid Growth Outlook

NanoRepro AG has released new revenue projections ahead of its Annual General Meeting. The company anticipates robust growth across its multi-brand health platform for the short-, medium-, and long-term. For the fiscal year 2026, NanoRepro forecasts revenues of approximately €18 million, reflecting a solid 12.5% year-on-year growth, largely driven by organic expansion.

Looking further ahead, the company estimates around €28 million in revenue by 2028, which exceeds prior expectations. This revision indicates a robust 20.5% compound annual growth rate from fiscal year 2025 to 2028. For 2030, NanoRepro targets €40 million in revenues, surpassing previous projections by €4.5 million. This suggests potential for both organic growth and acquisitions.

The company seeks shareholder approval for additional capital, enhancing flexibility for future acquisitions. Despite slight adjustments for near-term growth, NanoRepro maintains a BUY recommendation with a price target of €4.40.